Distinct cytokine patterns may regulate the severity of neonatal asphyxia—an observational study

[1]  K. Reymann,et al.  Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy , 2014, Kidney international.

[2]  Osman Ratib,et al.  Structured reporting: a fusion reactor hungry for fuel , 2014, Insights into Imaging.

[3]  C. Kuan,et al.  Blocking Lymphocyte Trafficking with FTY720 Prevents Inflammation-Sensitized Hypoxic–Ischemic Brain Injury in Newborns , 2014, The Journal of Neuroscience.

[4]  P. Marcovici,et al.  Journal Club: Structured radiology reports are more complete and more effective than unstructured reports. , 2014, AJR. American journal of roentgenology.

[5]  Xin Geng,et al.  Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection , 2013, Nature.

[6]  P. Lakatos,et al.  Accuracy of amplitude‐integrated electroencephalography in the prediction of neurodevelopmental outcome in asphyxiated infants receiving hypothermia treatment , 2013, Acta paediatrica.

[7]  M. Heneka,et al.  NLRP3 is activated in Alzheimer´s disease and contributes to pathology in APP/PS1 mice , 2012, Nature.

[8]  J. Toldi,et al.  Kynurenines in the CNS: recent advances and new questions , 2012, Nature Reviews Drug Discovery.

[9]  D. Azzopardi,et al.  Changes in serum cytokine and cortisol levels in normothermic and hypothermic term neonates after perinatal asphyxia , 2012, Inflammation Research.

[10]  L. Vécsei,et al.  The kynurenine system and immunoregulation , 2012, Journal of Neural Transmission.

[11]  B. Hemmer,et al.  Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE , 2011, The Journal of experimental medicine.

[12]  M. Torres-Ramos,et al.  On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. , 2011, Neurotoxicology and teratology.

[13]  Robert E. Synovec,et al.  Application of comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry method to identify potential biomarkers of perinatal asphyxia in a non-human primate model. , 2011, Journal of chromatography. A.

[14]  B. Vásárhelyi,et al.  [Systemic and immunomodulatory effects of whole body therapeutic hypothermia]. , 2011, Orvosi hetilap.

[15]  C. Sommer,et al.  Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. , 2011, Brain : a journal of neurology.

[16]  N. Marlow,et al.  Moderate hypothermia to treat perinatal asphyxial encephalopathy. , 2009, The New England journal of medicine.

[17]  T. Iwaki,et al.  Pivotal role of cerebral interleukin-17–producing γδT cells in the delayed phase of ischemic brain injury , 2009, Nature Medicine.

[18]  K. Ren,et al.  Role of interleukin-1β during pain and inflammation , 2009, Brain Research Reviews.

[19]  R. Hohlfeld,et al.  Neuro-immune crosstalk in CNS diseases , 2009, Neuroscience.

[20]  M. Levene,et al.  The TOBY Study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: A randomised controlled trial , 2008, BMC pediatrics.

[21]  Richard A Flavell,et al.  ‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulation , 2007, Immunological reviews.

[22]  K. Tracey,et al.  IL-1α and IL-1β Are Endogenous Mediators Linking Cell Injury to the Adaptive Alloimmune Response1 , 2007, The Journal of Immunology.

[23]  A. Valls-i-Soler,et al.  Hypoxic-Ischemic Injury in the Immature Brain – Key Vascular and Cellular Players , 2007, Neonatology.

[24]  Y. Wan,et al.  T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. , 2007, Immunity.

[25]  K. Tracey,et al.  IL-1alpha and IL-1beta are endogenous mediators linking cell injury to the adaptive alloimmune response. , 2007, Journal of immunology.

[26]  H. Aly,et al.  IL-1β, IL-6 and TNF-α and outcomes of neonatal hypoxic ischemic encephalopathy , 2006, Brain and Development.

[27]  Masahiko Kato,et al.  Elevation of Cytokine Concentrations in Asphyxiated Neonates , 2006, Neonatology.

[28]  Michael Loran Dustin,et al.  Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo , 2006, The Journal of experimental medicine.

[29]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[30]  H. Aly,et al.  IL-1beta, IL-6 and TNF-alpha and outcomes of neonatal hypoxic ischemic encephalopathy. , 2006, Brain & development.

[31]  F. Sutterwala,et al.  Transforming growth factor-β controls T helper type 1 cell development through regulation of natural killer cell interferon-γ , 2005, Nature Immunology.

[32]  S. Cousens,et al.  4 million neonatal deaths: When? Where? Why? , 2005, The Lancet.

[33]  T. Mcclanahan,et al.  IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.

[34]  F. Sutterwala,et al.  Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. , 2005, Nature immunology.

[35]  Britta Schöning,et al.  Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10. , 2004, Medical science monitor : international medical journal of experimental and clinical research.

[36]  N. Abbott.  Inflammatory Mediators and Modulation of Blood–Brain Barrier Permeability , 2000, Cellular and Molecular Neurobiology.

[37]  R. C. Silveira,et al.  Interleukin-6 and tumor necrosis factor-alpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. , 2003, The Journal of pediatrics.

[38]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[39]  W. Strober,et al.  Transforming Growth Factor (TGF)-β1–producing Regulatory T Cells Induce Smad-mediated Interleukin 10 Secretion That Facilitates Coordinated Immunoregulatory Activity and Amelioration of TGF-β1–mediated Fibrosis , 2003, The Journal of experimental medicine.

[40]  J. Antel,et al.  Vulnerability of Human Neurons to T Cell-Mediated Cytotoxicity1 , 2003, The Journal of Immunology.

[41]  F. Signore,et al.  Umbilical cord interleukin‐6 levels are elevated in term neonates with perinatal asphyxia , 2003, European journal of clinical investigation.

[42]  R. C. Silveira,et al.  Interleukin-6 and tumor necrosis factor-alpha levels in plasma and cerebrospinal fluid of term newborn infants with hypoxic-ischemic encephalopathy. , 2003, The Journal of pediatrics.

[43]  R. Schwarcz,et al.  Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities , 2002, Journal of Pharmacology and Experimental Therapeutics.

[44]  R. Buck,et al.  Longitudinal study of intracellular T cell cytokine production in infants compared to adults , 2002, Clinical and experimental immunology.

[45]  M. Raiteri,et al.  Direct evidence that release‐stimulating α7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals , 2002, Journal of neurochemistry.

[46]  R. Flavell,et al.  Transforming growth factor-beta in T-cell biology. , 2002, Nature reviews. Immunology.

[47]  P. Kazembe,et al.  Comparison of Serum and Cell-Specific Cytokines in Humans , 2001, Clinical Diagnostic Laboratory Immunology.

[48]  D. Ferriero,et al.  Human Perinatal Asphyxia: Correlation of Neonatal Cytokines with MRI and Outcome , 2001, Developmental Neuroscience.

[49]  H. Neumann,et al.  Fas Ligand (CD95L) Protects Neurons Against Perforin- Mediated T Lymphocyte Cytotoxicity1 , 2001, The Journal of Immunology.

[50]  T. Stone.  Kynurenines in the CNS: from endogenous obscurity to therapeutic importance , 2001, Progress in Neurobiology.

[51]  E. Saliba,et al.  Inflammatory Mediators and Neonatal Brain Damage , 2001, Neonatology.

[52]  M. Dihné,et al.  Focal ischemia induces transient expression of IL-6 in the substantia nigra pars reticulata , 2001, Brain Research.

[53]  Seong-Jin Kim,et al.  Disruption of T Cell Homeostasis in Mice Expressing a T Cell–Specific Dominant Negative Transforming Growth Factor β II Receptor , 2000, The Journal of experimental medicine.

[54]  R. Flavell,et al.  Abrogation of TGFβ Signaling in T Cells Leads to Spontaneous T Cell Differentiation and Autoimmune Disease , 2000 .

[55]  R. Flavell,et al.  Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. , 2000, Immunity.

[56]  E. Benveniste,et al.  Adhesion molecule expression and regulation on cells of the central nervous system , 1999, Journal of Neuroimmunology.

[57]  M. Schwartz,et al.  Innate and adaptive immune responses can be beneficial for CNS repair , 1999, Trends in Neurosciences.

[58]  A. Roberts,et al.  Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF‐β , 1999, The EMBO journal.

[59]  V. Ooi,et al.  Analysis of immunomodulating cytokine mRNAs in the mouse induced by mushroom polysaccharides. , 1999, Life sciences.

[60]  S. Ekholm,et al.  Intrathecal expression of proteins regulating apoptosis in acute stroke. , 1999, Stroke.

[61]  G. Cole,et al.  Apoptosis in a neonatal rat model of cerebral hypoxia-ischemia. , 1998, Stroke.

[62]  O. Saka,et al.  Predictive value of plasma and cerebrospinal fluid tumour necrosis factor-α and interleukin-1β concentrations on outcome of full term infants with hypoxic–ischaemic encephalopathy , 1998, Archives of disease in childhood. Fetal and neonatal edition.

[63]  Michael Schroeter,et al.  Inflammation and glial responses in ischemic brain lesions , 1998, Progress in Neurobiology.

[64]  R. P. Stroemer,et al.  Exacerbation of Ischemic Brain Damage by Localized Striatal Injection of Interleukin-1β in the Rat , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[65]  M. Blennow,et al.  Cytokine Response in Cerebrospinal Fluid after Birth Asphyxia , 1998, Pediatric Research.

[66]  N. Rothwell,et al.  Cerebral Interleukin-6 is Neuroprotective during Permanent Focal Cerebral Ischemia in the Rat , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[67]  A. Martín-Ancel,et al.  Interleukin-6 in the cerebrospinal fluid after perinatal asphyxia is related to early and late neurological manifestations. , 1997, Pediatrics.

[68]  H. Okano,et al.  ICE/CED‐3 Family Executes Oligodendrocyte Apoptosis by Tumor Necrosis Factor , 1997, Journal of neurochemistry.

[69]  M. Moskowitz,et al.  Expression of a Dominant Negative Mutant of Interleukin-1β Converting Enzyme in Transgenic Mice Prevents Neuronal Cell Death Induced by Trophic Factor Withdrawal and Ischemic Brain Injury , 1997, The Journal of experimental medicine.

[70]  M. Blennow,et al.  Enhanced Expression of Interleukin (IL)-1 and IL-6 Messenger RNA and Bioactive Protein after Hypoxia-Ischemia in Neonatal Rats , 1996, Pediatric Research.

[71]  D. Wallach,et al.  Inhibition of Tumor Necrosis Factor Alpha (TNFα) Activity in Rat Brain is Associated with Cerebroprotection after Closed Head Injury , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  J. Relton,et al.  Peripheral Administration of Interleukin-1 Receptor Antagonist Inhibits Brain Damage after Focal Cerebral Ischemia in the Rat , 1996, Experimental Neurology.

[73]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[74]  J. Kuiper,et al.  The influence of cytokines on the integrity of the blood-brain barrier in vitro , 1996, Journal of Neuroimmunology.

[75]  P. Beyne,et al.  Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. , 1996, Journal of chromatography. B, Biomedical applications.

[76]  D. Wallach,et al.  Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[77]  J. Garcìa,et al.  Interleukin-1 receptor antagonist decreases the number of necrotic neurons in rats with middle cerebral artery occlusion. , 1995, The American journal of pathology.

[78]  C. Goodyer,et al.  Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[79]  I. Aránguez,et al.  Expression of interferon-gamma receptors on murine oligodendrocytes and its regulation by cytokines and mitogens. , 1995, Immunology.

[80]  K. Hossmann,et al.  Reactive microglia in cerebral ischaemia: an early mediator of tissue damage? , 1995, Neuropathology and applied neurobiology.

[81]  J. Szaflarski,et al.  Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. , 1995, Stroke.

[82]  M. Mehler,et al.  Cytokines regulate the cellular phenotype of developing neural lineage species , 1995, International Journal of Developmental Neuroscience.

[83]  Y. Itoyama,et al.  Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. , 1995, Stroke.

[84]  Manuel Buttini,et al.  Peripheral lipopolysaccharide stimulation induces interleukin-1β messenger RNA in rat brain microglial cells , 1995, Neuroscience.

[85]  T. Mosmann,et al.  Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. , 1994, Journal of immunology.

[86]  M. Minami,et al.  An in situ hybridization study on interleukin-1 beta mRNA induced by transient forebrain ischemia in the rat brain. , 1994, Brain research. Molecular brain research.

[87]  M. Sporn,et al.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[88]  C. Janeway,et al.  Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma , 1993, The Journal of experimental medicine.

[89]  J. Merrill,et al.  Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological. , 1992, Developmental neuroscience.

[90]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.

[91]  T. Issekutz.  Inhibition of in vivo lymphocyte migration to inflammation and homing to lymphoid tissues by the TA-2 monoclonal antibody. A likely role for VLA-4 in vivo. , 1991, Journal of immunology.

[92]  H. Hatanaka,et al.  Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats , 1989, Neuroscience Letters.

[93]  T. Hirano,et al.  Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6 , 1988, Molecular and cellular biology.

[94]  M. Sporn,et al.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth , 1986, The Journal of experimental medicine.